19 completed, 5 recruiting, 5 terminated, 2 unknown. 33 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 33 | Completed 19, Recruiting 5, Terminated 5, Unknown 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 1 | 4 | Unknown 2, Completed 1, Terminated 1 |
Follow Chronic Cough: new trials by email Literature Review of Chronic Cough trials Research Report on Chronic Cough
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough BCS+inactive, BCS+active - Chronic Cough (CC), Refractory Chronic Cough | Phase 2 | Recruiting | University of Montana | 135 | 2026-08-13 | 2026-08-18 |
| A Study to Investigate the Efficacy and Safety of SC0032, a Magnesium Salt Oral Spray, in Adults With Refractory or Unexplained Chronic Cough SC0032, Placebo - Refractory Chronic Cough and Unexplained Chronic Cough | Phase 2 | Recruiting | Sensory Cloud, Inc. | 60 | 2026-07-13 | 2026-10-14 |
| The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC) NAL ER, Placebo - Refractory Chronic Cough | Phase 2 | Recruiting | Trevi Therapeutics | 100 | 2026-06-22 | 2026-10-13 |
| A Phase 2 Study of HW091077 in Participants With Refractory Chronic Cough Or Unexplained Chronic Cough (RCC/UCC). HW091077, Matching placebo to HW091077 - Refractory Chronic Cough | Phase 2 | Not yet recruiting | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | 180 | 2026-05-01 | 2026-03-19 |
| Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF) ME-015 (Suplatast Tosilate), Identical placebo - Idiopathic Pulmonary Fibrosis, Cough | Phase 2 | Active not recruiting | Melius Pharma AB | 40 | 2024-04-01 | 2025-04-09 |
| A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough TCR1672 tablet - Refractory Chronic Cough | Phase 1 / Phase 2 | Unknown | Beijing Tide Pharmaceutical Co., Ltd | 72 | 2024-02-01 | 2024-01-19 |
| Refractory Chronic Cough Improvement Via NAL ER (RIVER) NAL ER, Placebo - Refractory Chronic Cough | Phase 2 | Completed | Trevi Therapeutics | 66 | 2023-11-30 | 2026-03-30 |
| A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough HRS-2261 oral tablet, Matching placebo to HRS-2261 - Refractory Chronic Cough | Phase 2 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 97 | 2023-03-09 | 2026-01-21 |
| A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough ADX-629, Placebo - Chronic Cough | Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 51 | 2022-04-07 | 2025-02-28 |
| Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough Amitriptyline 25 MG, Amitriptyline 50 MG, Duloxetine 30 MG - Interstitial Lung Disease | Phase 2 | Recruiting | Mayo Clinic | 25 | 2021-11-01 | 2026-01-21 |
| Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough Duloxetine 30 MG, Duloxetine 60 MG, Amitriptyline 25 MG - Refractory Chronic Cough | Phase 2 | Recruiting | Mayo Clinic | 50 | 2021-11-01 | 2026-01-21 |
| A Study of Efficacy and Safety of AX-8 in Chronic Cough AX-8, Part 1 of the study, Placebo, Part 1 of the study, AX-8, Part 2 of the study - Chronic Cough | Phase 2 | Completed | Axalbion SA | 108 | 2021-08-11 | 2025-09-08 |
| Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough BLU-5937, Placebo - Refractory Chronic Cough | Phase 2 | Completed | Bellus Health Inc. - a GSK company | 310 | 2020-12-07 | 2021-12-13 |
| Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough BAY1817080, Placebo - Refractory and/or Unexplained Chronic Cough | Phase 2 | Completed | Bayer | 310 | 2020-10-02 | 2022-08-18 |
| Evaluation of S-600918 in Adults With Refractory Chronic Cough S-600918, Placebo to S-600918 - Chronic Cough | Phase 2 | Completed | Shionogi | 406 | 2020-02-13 | 2024-03-27 |
| A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough BLU-5937, Placebo - Chronic Refractory Cough | Phase 2 | Terminated | Bellus Health Inc. - a GSK company | 68 | 2019-07-10 | 2021-08-03 |
| A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF RVT-1601, Placebo - Persistent Cough in IPF, Chronic Cough | Phase 2 | Terminated | Respivant Sciences GmbH | 108 | 2019-03-29 | 2020-06-11 |
| A Dose Escalation Study of Bradanicline in Refractory Chronic Cough Bradanicline, Placebo - Chronic Cough | Phase 2 | Completed | Attenua, Inc. | 46 | 2018-11-05 | 2019-06-20 |
| A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough GSK2798745, Placebo - Cough | Phase 1 / Phase 2 | Terminated | GlaxoSmithKline | 17 | 2018-04-05 | 2019-10-02 |
| Study of Gefapixant (MK-7264) in Adult Japanese Participants With Unexplained or Refractory Chronic Cough (MK-7264-033) Gefapixant 45 mg, Placebo - Chronic Cough | Phase 2 | Completed | Merck Sharp & Dohme LLC | 23 | 2018-03-16 | 2019-10-17 |
Showing 20 of 33. Sign in to see all of them.
Cough (12) · Fibrosis (2) · Pulmonary Fibrosis (2) · Asthma (1) · Gastroesophageal Reflux (1) · Idiopathic Pulmonary Fibrosis (1) · Inflammation (1) · Lung Diseases, Interstitial (1) · Pulmonary Disease, Chronic Obstructive (1) · cough hypersensitivity syndrome (1) · upper airway cough syndrome (1)
Pathological Conditions, Signs and Symptoms (33) · Respiration Disorders (33) · Respiratory Tract Diseases (33) · Signs and Symptoms (33) · Signs and Symptoms, Respiratory (33) · Cough (21) · Lung Diseases (4) · Pathologic Processes (4) · Lung Diseases, Interstitial (2) · Lung Diseases, Obstructive (2) · Bronchial Diseases (1) · Chronic Disease (1) · Deglutition Disorders (1) · Digestive System Diseases (1) · Disease Attributes (1)
Gefapixant (7) · Amitriptyline (2) · BLU-5937 (2) · Duloxetine Hydrochloride (2) · Nalbuphine (2) · ADX-629 (1) · GSK2798745 (1) · Interferon-alpha (1) · MO 113 (1) · Pregabalin (1) · Zinc Acetate (1) · indantadol (1) · serlopitant (1) · sivopixant (1) · suplatast tosilate (1)
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (6) · Bayer (2) · Bellus Health Inc. - a GSK company (2) · Mayo Clinic (2) · Trevi Therapeutics (2) · Ainos, Inc. (f/k/a Amarillo Biosciences Inc. (1) · Aldeyra Therapeutics, Inc. (1) · Attenua, Inc. (1) · Axalbion SA (1) · Beijing Tide Pharmaceutical Co., Ltd (1) · GlaxoSmithKline (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (1) · Johns Hopkins University (1) · Melius Pharma AB (1)
United Kingdom (14) · United States (14) · Canada (6) · Czechia (4) · Germany (3) · Japan (3) · Netherlands (3) · Poland (3) · Australia (2) · Belgium (2) · Hungary (2) · Italy (2) · Turkey (Türkiye) (2) · Argentina (1) · China (1)
Vivek N Iyer, MD (2) · Ahmet Tutuncu, MD, PhD (1) · Amanda Gillespie, PhD (1) · Ashley Woodcock, Prof. (1) · Jacky Smith (1) · Jacky Smith, MD, Ph.D. (1) · Janet Holbrook, PhD (1) · Kayvan Amjadi, MD (1) · Laurie J Slovarp, PhD (1)
PMID 25467586, PMID 28923239, PMID 31023843, PMID 31949115, PMID 32109425, PMID 33825965, PMID 33986030, PMID 34697975, PMID 35614875, PMID 35624408, PMID 36348054, PMID 36512069, PMID 37261531, PMID 38044419, PMID 40043302, PMID 40498172
2015 (4), 2017 (3), 2019 (2), R34HL132369 (1)